ENDOCYTE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $500,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Endocyte, Inc. -- ECYT

        Print
| Source: Kahn Swick & Foti, LLC

NEW ORLEANS, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2014 to file lead plaintiff applications in a securities class action lawsuit against Endocyte, Inc. (Nasdaq:ECYT), if they purchased the Company's securities during the period between March 21, 2014 and May 2, 2014, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of Indiana.

What You May Do

If you purchased shares of Endocyte and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850, or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com) or KSF Partner Melinda Nicholson (melinda.nicholson@ksfcounsel.com). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 25, 2014.

About the Lawsuit

Endocyte and certain of its executives are charged with issuing a series of materially false and misleading statements during the Class Period, violating federal securities laws.

The complaint accuses the defendants failed to disclose that the Committee for Medicinal Products for Human Use of the European Medicines Agency's "positive opinions" for Endocyte's experimental drug VYNFINIT®, used to treat platinum-resistant ovarian cancer, using testing methods known as response evaluation criteria in solid tumors ("RECIST") were based on the testing criteria called RECIST 1.0 while, the pending analysis for the "Conditional Marketing Authorisations" would be using the more stringent RECIST 1.1 testing criteria. On May 2, 2014, Endocyte disclosed that VYNFINIT® was found ineffective under RECIST 1.1.

On this news, the price of Endocyte's stock plummeted by 61%.

About Kahn Swick & Foti, LLC

To learn more about KSF, whose partners include the Former Louisiana Attorney General, Charles C. Foti, Jr., and other lawyers with significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders, you may visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner

Melinda Nicholson, Partner

1-877-515-1850
206 Covington St.
Madisonville, LA 70447